Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Gastroenterology
Treatment with Anti-Tumor Necrosis Factor (anti-TNF) therapy has become a mainstay of therapy for patients with CD who are unresponsive to conventional medical management. Currently there are three anti-TNF antibodies that have been approved by the US Food and Drug Administration for the treatment of CD, namely infliximab, adalimumab and certolizumab pegol (CZP). Several double blind placebo controlled trials determined that CZP is effective as induction and maintenance treatment in adult patients with CD regardless of their prior exposure to other anti-TNF antibodies. This review discusses the efficacy of CZP and adherence to therapy with anti-TNF antibodies in patients with CD.
PDF (563.81 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
Supplementary Files 1 (8.79 MB WMV FORMAT)
BibTex citation (BIBDESK, LATEX)